



HEALTHCARE

Optimizing Lifecycle Management

Maximizing commercial lifespan through label expansion and combination products

By Gaurav Misra

Gaurav Misra

Gaurav Misra is a strategy consultant for the biopharmaceutical sector. He has an undergraduate degree in Chemistry and an MBA from the Richard Ivey School of Business, where he specialized in Healthcare & Life Sciences. Gaurav has eight years' experience of many issues that are central to effective lifecycle management of biopharmaceutical products. He has participated in and led projects on strategic planning, health economics, promotions resource allocation and analytical due diligence for global biopharmaceutical companies and healthcare investors.

Copyright © 2009 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Optimizing Lifecycle Management

Executive summary	8	
Product lifecycle and management challenges	8	
Influencing the commercial lifespan of the drug	9	
Accessing broader patient populations	10	
Fixed dose combinations	11	
Chapter 1	Product lifecycle and management challenges	14
Summary		14
Introduction		15
The lifecycle of biopharmaceutical drugs		15
Development lifecycle		17
Commercial lifecycle		22
Managing the lifecycle		22
Longer development time		23
Slower product uptake via reimbursement hurdles		24
Peak sales potential is reduced by higher competition		25
Earlier lifecycle decline due to therapeutic substitution		26
Chapter 2	Influencing the commercial lifespan of a drug	30
Summary		30
Bargaining power of biopharmaceutical brands		31
Brand equity		31
Patent protection and “freedom to operate”		32
Strategic patenting		33
Patent prosecution superhighway		35
Patent protection for biologics		35

Data exclusivity	36
Difference between data exclusivity and patent protection	40
8+2+1 system in the EU	40
Data exclusivity in the US	42
Data exclusivity in Japan	43
Data exclusivity in the context of biologics	44

Chapter 3 Accessing broader patient populations 46

Summary	46
Drug labeling and market access	47
Off-label drug usage	47
Commercial incentives and disincentives	48
Payors stance on off-label reimbursement	49
Case study: Avastin and Lucentis	51
Expanding the label	53
Role in product lifecycle management	53
New indications	53
Pediatric extensions and special populations	54
Modified indications and expanded usage	54
Case study: Yaz	55
Case study: Remicade	58
Indication expansion	59
Choosing the primary indication	61
Related versus unrelated indications	63
Sequence of indication expansion	64
Timing of indication expansion	65
Launching early in commercial lifecycle	68
Launching late in commercial lifecycle	69
Seroquel: Using indication expansion and drug reformulation synergistically	70
Recent trends in indication expansion	72
Indication expansion for NDAs	72
Indication expansion for biologics	75

Chapter 4 Fixed dose combinations 80

Summary	80
Introduction	81
Clinical challenges in FDC development	81
FDC patents	82
Data exclusivity for FDCs	83
Role in product lifecycle maximization	83

Case study: Advair's role in GSK's asthma franchise	85
Case study: How Vytorin influenced Zocor's patent expiry	88
Case study: BiDil's value proposition reinvented	90
FDC uptake by geography	91
Case study: FDCs for hypertension	91
Clinical rationale	93
Synergistic efficacy or safety	94
Easier Rx management	95
Correlation between FDC usage and drug compliance	95
Correlation between drug compliance & improved clinical outcomes	96
FDC usage by therapy area	96
Key success factors and competitive hurdles	98
Endorsement by treatment guidelines	98
Perceived synergy effects over free combination	99
Compliance advantage over the free combination	99
Usage of mono compounds prior to FDC launch	99
Discount compared to cheapest free combination	100
Time-to-LOE of parent brand	101

Chapter 5	Appendix	103
Primary research methodology		103
Glossary		107
Index		111

List of Figures

Figure 1.1:	Summary of lifecycle of medicinal drugs	17
Figure 1.2:	Transition probabilities for clinical phases	18
Figure 1.3:	Out-of-pocket and capitalized costs of developing a drug (\$m)	19
Figure 1.4:	Time taken for development of new pharma & biotech drugs	20
Figure 1.5:	Approval timelines at CDER for priority NDAs, 1999-08	21
Figure 1.6:	Approval timelines at CDER for standard NDAs, 1999-08	21
Figure 1.7:	Imperatives of efficient lifecycle management	23
Figure 1.8:	Increasing importance of payors as stakeholders	24
Figure 1.9:	Tougher payor environments are slowing product uptake	25
Figure 1.10:	Therapeutic substitution and formulary access	27
Figure 2.11:	8+2+1 data exclusivity system in Europe	41
Figure 2.12:	Data exclusivity and patent protection in the US	43
Figure 3.13:	On and off-label decision making by payors	50
Figure 3.14:	Off-label usage of Avastin: a pharmacoeconomic model for wet AMD	52
Figure 3.15:	Yaz: Label expansion & sales growth - US (\$m), 2006-08	57
Figure 3.16:	Remicade: Label expansion & sales growth - US (\$m), 2001-08	59

Figure 3.17:	Time between launch of original and new indications in the US (by ATC), 1999-08	66
Figure 3.18:	Time between launch of original and new indications in the US (by ATC), 1999-08 (contd)	67
Figure 3.19:	Considerations in launching new indications early in the lifecycle	69
Figure 3.20:	Considerations in launching new indications late in the lifecycle	70
Figure 3.21:	Lifecycle management: Seroquel and Seroquel XR	71
Figure 3.22:	New indication approvals for NDAs, 1999-2008	73
Figure 3.23:	New indication approvals for Orphan drugs, 1999-08	73
Figure 3.24:	New indication approvals with priority reviews, 1999-08	74
Figure 3.25:	Increasing clinical and commercial potential for Remicade	77
Figure 4.26:	FDC approvals in the US, 1999-08	84
Figure 4.27:	Advair: FDA approvals and patent protection	86
Figure 4.28:	Advair-Serevent sales in the US: maintaining revenues post patent expiry of Flovent	87
Figure 4.29:	Zocor-Vytorin-Zetia brand timeline	88
Figure 4.30:	Cushioning the patent cliff: Zocor-Vytorin-Zetia sales in US (\$m), 2001-08	89
Figure 4.31:	FDC usage for hypertension across major markets	93
Figure 4.32:	Drug classes with maximum FDC approvals in the US, 1999-08	97

List of Tables

Table 2.1:	Data exclusivity periods by country	39
Table 3.2:	Success drivers and barriers in indication expansion	61
Table 3.3:	Unmet needs prevalent within an indication	62
Table 3.4:	Commercial considerations in prioritizing new indications	62
Table 3.5:	Disease areas and related sub-populations for hypertension and heart failure	63
Table 3.6:	New indication approvals by drug class, 1999-08	75
Table 4.7:	FDC case studies	81